AbbVie (ABBV)
(Delayed Data from NYSE)
$201.20 USD
-0.48 (-0.24%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $201.20 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$201.20 USD
-0.48 (-0.24%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $201.20 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum C VGM
Zacks News
C3.ai's (AI) Stock Is Soaring After Earnings But is it Time to Buy?
by Shaun Pruitt
As one of the more promising artificial intelligence companies, let's see if it's time to buy C3.ai's (AI) stock after revenue and contract growth fuel its post-earnings rally.
Pharma Stock Roundup: FDA Priority Tag to SNY, ABBV Filings, CHMP Nod for AZN, JNJ, MRK
by Kinjel Shah
The FDA grants priority review status to Sanofi's (SNY) and AbbVie's (ABBV) sBLAs for Dupixent and Epkinly, respectively
Is iShares Core High Dividend ETF (HDV) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for HDV
Should First Trust Value Line Dividend ETF (FVD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FVD
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
Pharma Stock Roundup: Pfizer's Velsipity Receives EU Nod, ABBV Gets New CEO & More
by Kinjel Shah
European Commission approves Pfizer's (PFE) Velsipity ulcerative colitis (UC) pill. AbbVie (ABBV) appoints Robert A. Michael as the new CEO.
AbbVie (ABBV) is a Top Dividend Stock Right Now: Should You Buy?
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
AbbVie (ABBV) Announces Appointment of New CEO Robert Michael
by Zacks Equity Research
Robert Michael is set to succeed Richard A. Gonzalez as AbbVie's (ABBV) CEO, effective Jul 1, 2024.
Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PJP
Is ProShares S&P 500 Dividend Aristocrats ETF (NOBL) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for NOBL
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income
by Zacks Equity Research
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
Ironwood (IRWD) Q4 Earnings Miss, Revenues Beat Marginally
by Zacks Equity Research
Ironwood's (IRWD) fourth-quarter 2023 earnings lag estimates while revenues beat the same marginally. Linzess collaboration revenues drive the top line.
The Zacks Analyst Blog Highlights AbbVie, Applied Materials, American Express, Centene and Aspen
by Zacks Equity Research
AbbVie, Applied Materials, American Express, Centene and Aspen are included in this Analyst Blog.
Top Stock Reports for AbbVie, Applied Materials & American Express
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), Applied Materials, Inc. (AMAT) and American Express Company (AXP).
3 Top Dividend Stocks to Maximize Your Retirement Income
by Zacks Equity Research
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Novartis (NVS) to Buy MorphoSys & Add Late-Stage Oncology Drug
by Zacks Equity Research
Novartis (NVS) announces an agreement to acquire Germany-based MorphoSys AG and add the latter's late-stage candidate pelabresib to its pipeline.
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Is WisdomTree U.S. High Dividend ETF (DHS) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DHS
This is Why AbbVie (ABBV) is a Great Dividend Stock
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks
by Zacks Equity Research
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, AbbVie and Novartis
by Zacks Equity Research
Eli Lilly, Novo Nordisk, AbbVie and Novartis have been highlighted in this Industry Outlook article.
AbbVie (ABBV) Q4 Earnings Beat, Raises Sales View for Key Drugs
by Zacks Equity Research
AbbVie???s (ABBV) fourth-quarter earnings and sales beat estimates. Management hikes the 2027 forecast for new immunology drugs to more than $27 billion.
Nonfarm Payrolls Increased More Than Expected
by Zacks Equity Research
Nonfarm Payrolls Increased More Than Expected
BLS Jobs Up Big: 353K, 3.7% Unemployment
by Mark Vickery
353K new jobs created for January are nearly double the 180K or so analysts were looking for.